Mosanna Therapeutics
Pioneering a pharmaceutical nasal spray to restore natural airway control for sleep apnea.
Redwood City, United States · Founded 2022 · $80.0M raised
- Headquarters
- Redwood City, California
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- mosanna.com
- Total Funding
- $80.0M
- Last Round
- $80.0M Series AJun 2025
- Rounds
- 3
About
Mosanna Therapeutics is a clinical-stage biotech company developing a novel pharmaceutical approach to treating obstructive sleep apnea (OSA), which affects an estimated 1 billion people globally. Its lead therapy, MOS118, is an easy-to-use nighttime nasal spray designed to restore the body's natural upper airway reflex during sleep — treating OSA as a neurological and muscular dysfunction rather than a purely mechanical problem. This positions MOS118 as a non-invasive alternative to CPAP and other mechanical treatments. The $80 million Series A was led by Pivotal bioVenture Partners and EQT Life Sciences, with co-leads Forbion, Broadview Ventures, and Norwest. MOS118 is currently in Phase 1 clinical trials, with the new funding advancing it through Phase 2. Mosanna has offices in Redwood City, California and Basel, Switzerland.
Summary
Mosanna Therapeutics is a Biotech company based in Redwood City, United States, founded in 2022. It has raised $80.0M in total across 3 rounds, most recently a $80.0M Series A round in Jun 2025. Investors include Pivotal bioVenture Partners, Forbion Capital Partners and Broadview Ventures.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...